![nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.21.01728/asset/images/large/jco.21.01728f3.jpeg)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology
![Estimating Aadi Biosciences' (AADI) chances of success for tumor agnostic approval in malignant solid tumors with pathogenic TSC1 or TSC2 inactivating alterations. Estimating Aadi Biosciences' (AADI) chances of success for tumor agnostic approval in malignant solid tumors with pathogenic TSC1 or TSC2 inactivating alterations.](https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1dc07c3f-90b6-4c35-b702-f17fa3683077_2540x1434.png)
Estimating Aadi Biosciences' (AADI) chances of success for tumor agnostic approval in malignant solid tumors with pathogenic TSC1 or TSC2 inactivating alterations.
![nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2021/jco.2021.39.issue-33/jco.21.01728/20231020/images/keyimage.jpg)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology
![Vivek Subbiah, MD on X: "🚨Today FDA approved a drug nab-sirolimus for an ultra rare sarcoma- a unicorn🦄 -PECOMA. 👉🏼Sarcomas are more than 150 different types. 👉🏼Time to identify targets & drugs Vivek Subbiah, MD on X: "🚨Today FDA approved a drug nab-sirolimus for an ultra rare sarcoma- a unicorn🦄 -PECOMA. 👉🏼Sarcomas are more than 150 different types. 👉🏼Time to identify targets & drugs](https://pbs.twimg.com/media/FE4sU8jXMAknTLe.jpg)
Vivek Subbiah, MD on X: "🚨Today FDA approved a drug nab-sirolimus for an ultra rare sarcoma- a unicorn🦄 -PECOMA. 👉🏼Sarcomas are more than 150 different types. 👉🏼Time to identify targets & drugs
![Full article: Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies Full article: Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies](https://www.tandfonline.com/cms/asset/5af49680-ddc2-4e06-92f9-630917522eb6/ianb_a_1408123_uf0001_c.jpg)
Full article: Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies
![Aadi Bioscience initiates rolling submission of NDA to FDA for nab-sirolimus for advanced malignant PEComa - Pharmaceutical Business review Aadi Bioscience initiates rolling submission of NDA to FDA for nab-sirolimus for advanced malignant PEComa - Pharmaceutical Business review](https://pharmaceutical-business-review.com/wp-content/uploads/2020/06/FDA-drug.jpg)
Aadi Bioscience initiates rolling submission of NDA to FDA for nab-sirolimus for advanced malignant PEComa - Pharmaceutical Business review
![Albumin-bağlı Rapamisin (nab-sirolimus) Amerika Birleşik Devletleri'nde Listelenmek İçin Uygulandı! - Sektörel Haberler - Haberler - Hefei Home Sunshine İlaç Teknolojisi Co, Ltd Albumin-bağlı Rapamisin (nab-sirolimus) Amerika Birleşik Devletleri'nde Listelenmek İçin Uygulandı! - Sektörel Haberler - Haberler - Hefei Home Sunshine İlaç Teknolojisi Co, Ltd](http://tr.hsp-pharma.com/Content/uploads/2020524038/20200709173311e177f5eb432d4683aaa2d54890a433bf.png)
Albumin-bağlı Rapamisin (nab-sirolimus) Amerika Birleşik Devletleri'nde Listelenmek İçin Uygulandı! - Sektörel Haberler - Haberler - Hefei Home Sunshine İlaç Teknolojisi Co, Ltd
![Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting](https://mma.prnewswire.com/media/1889345/Aadi_Bioscience.jpg?p=twitter)